Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SymBiosis Capital Management is a biotechnology venture capital firm based in Bentonville, Arkansas. Founded in 2019 and publicly launched in October 2021, the firm focuses on advancing biotherapeutics innovations. SymBiosis partners with companies developing solutions for life-threatening diseases, utilizing novel therapeutic platforms and emphasizing manufacturability. The firm operates within the unique context of Northwest Arkansas, an area known for its ties to the Walmart and Walton family ecosystem.
As of 2021, SymBiosis has built a portfolio of over 20 companies, demonstrating its commitment to investing in the biotechnology sector. The firm has established itself as a key player in the industry, particularly through initiatives like the BioAR Trial Accelerator, which aims to expedite the market entry of biotherapeutics. This program enhances access to clinical care and innovative medicines for Arkansans while supporting the growth of its portfolio companies.
SymBiosis invests in biotechnology companies across various modalities, including biologics, cell therapy, genetic medicine, and small molecules. Their investment strategy is agnostic to specific diseases, focusing instead on companies with lead candidates that are reaching human proof-of-concept or are expected to do so. The firm targets investments in late pre-clinical through clinical stages, ensuring that the companies they partner with are positioned for significant advancements in therapeutic development.
Initial investments typically range from $5 million to $15 million, with the potential to scale to $30 million or more across multiple financing rounds. SymBiosis emphasizes partnerships with companies that utilize novel therapeutic platforms and design for manufacturability, ensuring that the solutions developed can be effectively brought to market.
SymBiosis has a diverse portfolio of biotechnology companies, including:
This portfolio reflects SymBiosis's commitment to investing in companies that are at the forefront of biotherapeutics innovation, targeting critical health challenges across various therapeutic areas.
Chidozie Ugwumba — Managing Partner. Chidozie leads the firm and has a strong background in biotechnology investments, focusing on partnering with companies developing groundbreaking medicines.
Caleb Kreutner — Vice President, Operations. Caleb oversees operational aspects and ensures efficient management of portfolio companies.
Aleksei Cremo — Vice President, Investments. Aleksei is responsible for sourcing and evaluating new investment opportunities within the biotech sector.
Catherine Shoults, PhD — Vice President, AI & Analytics. Catherine brings expertise in data analytics and artificial intelligence to support investment decisions.
Brendon Dobbs — Associate, AI & Analytics. Brendon assists in analyzing data trends and supporting portfolio companies with AI-driven insights.
Geraldine Schott, PhD — Associate, Investments. Geraldine focuses on evaluating biotech investments and supporting due diligence processes.
Allie Ivy, PhD — Analyst, Investments. Allie conducts market research and analysis to identify promising biotech startups.
Aryan Vora — Analyst, Investments. Aryan supports investment evaluations and portfolio management.
Juchan Lim, PhD — Analyst, Investments. Juchan specializes in scientific evaluations of potential investments.
Trevor Goethe — Analyst, Operations. Trevor assists in operational management and coordination within the firm.
Ramona Mullen — Chief of Staff. Ramona oversees administrative functions and supports the leadership team.
Sarah Hernandez — Administrative Coordinator. Sarah manages day-to-day administrative tasks within the firm.
Operating Advisors: Andrew Badley, MD; Gene Kym, PhD; Helen Kuhlman, PhD; Sandy Zweifach; Sue Preston; Tony Khoury.
To pitch to SymBiosis, founders should visit their website at symbiosis.vc for detailed instructions. The firm prefers pitches that include a clear overview of the technology, the problem it addresses, and the team behind the project. Founders should also outline their development milestones and funding needs.
SymBiosis typically responds to pitches within a few weeks, and they encourage warm introductions through mutual connections in the biotech community.
SymBiosis is associated with the BioAR Trial Accelerator, designed to assist biotherapeutics companies in late pre-clinical stages.
In October 2022, SymBiosis announced its partnership with HealthTech Arkansas to form the BioAR Trial Accelerator, aimed at expediting the market entry of biotherapeutics. This initiative enhances access to clinical care and innovative medicines for Arkansans.
SymBiosis has been actively engaging with its portfolio companies, as evidenced by recent blog posts detailing collaborations, financing rounds, and clinical trial updates. Topics include FDA submissions and positive trial data, indicating a strong focus on advancing their portfolio's innovations in the biotech space.
What are SymBiosis's investment criteria?
SymBiosis invests in biotechnology companies that are developing solutions for life-threatening diseases. They focus on companies with lead candidates that are reaching human proof-of-concept or are expected to do so with their initial investment round. The firm is agnostic to specific diseases, provided that the endpoints for approval are well-established and objective.
How can I apply or pitch to SymBiosis?
Founders interested in pitching to SymBiosis can visit their website at symbiosis.vc for more information on the application process. They encourage startups to present their innovative solutions and how they align with the firm's investment thesis.
What makes SymBiosis different from other venture capital firms?
SymBiosis distinguishes itself by focusing exclusively on biotechnology innovations that target life-threatening diseases. Their investment strategy emphasizes manufacturability and the potential for industrial scale, which is critical for biotherapeutics.
What is the geographic scope of SymBiosis's investments?
SymBiosis primarily invests in companies based in the United States, although their investment strategy is agnostic to specific geographic locations. They are open to opportunities that align with their focus on biotherapeutics.
What is the typical check size for investments?
SymBiosis typically invests between $5 million and $15 million in initial funding rounds, with the potential to scale investments to $30 million or more across multiple financing rounds.
What kind of support does SymBiosis provide to portfolio companies?
SymBiosis adds value to its portfolio companies by providing access to a network of industry experts and resources. They facilitate faster market entry for biotherapeutics through initiatives like the BioAR Trial Accelerator and support companies in navigating clinical trials and regulatory approvals.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.